Project acronym: LIVERHOPE

Project full title: "Simvastatin and Rifaximin as new therapy for patients with decompensated cirrhosis"

News archive


spacer

arrow

27th Ed. International Congress “Trends and perspectives in hepatology"

30 November - 1 December 2018


At the international conference "Trends and Perspectives in Hepatology 2018" in Padova, Italy, Pere Ginès presented the LIVERHOPE project in the session "Targeting key pathogenic events in order to prevent cirrhosis progression"

spacer

 

arrow

LIVERHOPE first Annual Meeting

June 15, 2018 - Barcelona (TBA)


pdf Agenda
pdf Participant list
pdf Info

arrow

EASL Clinical Practice Guidelines

Announcement that 6 investigators from the LiverHope Consortium have participated in the committee that has prepared the EASL Clinical Practice Guidelines for management of patients with decompensated cirrhosis recently presented at the ILC 2018 in Paris and published in Journal of Hepatology

arrow

EASL ILC

The P.Is of the clinical centres met at the recent EASL ILC meeting in Paris to discuss the Efficacy trial

arrow

Datebase of the safety

The datebase of the safety trial has been closed

arrow

EASL ILC 2018

At EASL ILC 2018, Pere Ginès presented the LIVERHOPE in a EU Grant application session, the title of his talk was "How I did it"

arrow

45 patients

January 2018 - The recruitment period for the LIVERHOPE SAFETY study has been completed - 45 patients are currently eligible for analysis

spacer
arrow

40 patients

November 2017 - 40 patients (89%) validated for the Safety Study and are currently eligible for analysis

arrow

First two patients

August 2017 - the first two patients were enrolled in the Safety Study in the Hospital Clínic

arrow

LIVERHOPE

June 2017 - website online